Inflammation and poor response to treatment with erythropoietin in chronic kidney disease

J Bras Nefrol. 2015 Apr-Jun;37(2):255-63. doi: 10.5935/0101-2800.20150039.
[Article in English, Portuguese]

Abstract

The prevalence of kidney chronic disease (CKD) has increased in recent years and several risk factors have been associated with the onset and progression of CDK, such as obesity, hypertension and diabetes mellitus. In addition, anemia is one of the complications of CRD, mainly by iron and erythropoietin (EPO) deficiency and the management of this situation is with exogenous erythropoietin, but patients undergoing dialysis present chronic inflammatory process followed by EPO resistance and anemia, malnutrition, worse of atherosclerosis and increased mortality ratio. The aim of this study was to review the association of erythropoietin resistance and chronic inflammatory process in patients with chronic renal disease.

Publication types

  • Review

MeSH terms

  • Anemia / drug therapy*
  • Anemia / etiology*
  • Drug Resistance
  • Erythropoietin / therapeutic use*
  • Humans
  • Inflammation / etiology*
  • Renal Insufficiency, Chronic / complications*
  • Treatment Outcome

Substances

  • EPO protein, human
  • Erythropoietin